In comparison to other antidiabetic therapies, DPP-4 inhibitors are preferable to agents associated with hypoglycemia and weight gain, though SGLT2 inhibitors exhibit superior benefits in heart failure [98]. The gene discussed is DPP4; the disease is heart failure.